Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01907-17. doi: 10.1128/AAC.01907-17. Print 2018 Jan.

Authors

Kwok-Chiu Chang¹, Wing-Wai Yew², Ying Zhang³

Affiliations

¹ Tuberculosis & Chest Service, Centre for Health Protection, Department of Health, Hong Kong, China kc_chang@dh.gov.hk.
² Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
³ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

No abstract available

Keywords: drug resistant; pyrazinamide; tuberculosis.

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use*
Humans
Microbial Sensitivity Tests / methods
Mycobacterium tuberculosis / drug effects
Pyrazinamide / therapeutic use*
Tuberculosis, Multidrug-Resistant / drug therapy*
World Health Organization

Substances

Antitubercular Agents
Pyrazinamide

Grants and funding

R01 AI099512/AI/NIAID NIH HHS/United States